Acrivon Therapeutics
- Company typePublic
- Founded2018
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Acrivon Therapeutics firmographics
Firmographics- Name
- Acrivon Therapeutics
- Legal name
- Acrivon Therapeutics, Inc.
- Website
- https://acrivon.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Acrivon Therapeutics industry classification
Industry- Product category
- Precision Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
Keywords
Where Acrivon Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Acrivon Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Drug Development and Commercialization: Acrivon is a clinical-stage precision oncology company focused on developing targeted cancer therapies. As an unprofitable biotech, it has no current revenue. Future revenue will come from commercialization of drug candidates upon regulatory approval, with potential for co-development partnerships and licensing arrangements.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Acrivon Therapeutics product offering
Product offeringCore offering
Acrivon Therapeutics is a clinical-stage precision oncology company developing targeted cancer therapies paired with proprietary OncoSignature companion diagnostics. Its lead program ACR-368 (a CHK1/2 inhibitor in-licensed from Eli Lilly) is in registrational-intent Phase 2b for endometrial cancer and platinum-resistant ovarian cancer, supported by the AP3 platform that uses mass spectrometry-based phosphoproteomics with automated tumor biopsy imaging to match drug mechanisms to protein-activity-driven tumor biology rather than genomic alterations.
Product overview
Acrivon Therapeutics is a clinical-stage precision oncology company developing a pipeline of targeted cancer therapies powered by its proprietary AP3 (Acrivon Predictive Precision Proteomics) platform. The company's portfolio includes three drug candidates: ACR-368 (lead program, CHK1/2 inhibitor in Phase 2 for endometrial cancer with FDA Fast Track designation), ACR-2316 (WEE1/PKMYT1 inhibitor in Phase 1/2), and ACR-6840 (CDK11 inhibitor in IND-enabling studies). These drug candidates are paired with the company's OncoSignature companion diagnostic tests, which use automated quantitative proteomic tissue imaging to identify patients whose tumors are predicted to be sensitive based on protein activity measurement rather than genomic alterations.
Differentiator
Problem solved
Functional benefit
Products and services
- ACR-368 (Prexasertib) ACR-368 (prexasertib) is a clinically-advanced, potent selective kinase inhibitor of DNA Damage Response checkpoint kinases CHK1 and CHK2, demonstrating deep durable single-agent anti-tumor clinical activity including complete responses in platinum-resistant ovarian cancer and other high unmet need solid tumor types. It is paired with the OncoSignature companion diagnostic for patient selection and has shown a 52% confirmed overall response rate in serous endometrial cancer and a 67% overall response rate in OncoSignature-positive serous endometrial cancer patients in Phase 2b studies.
- ACR-2316 ACR-2316 is a selective, dual WEE1/PKMYT1 inhibitor developed using Acrivon's AP3 platform and co-crystallography-driven design, currently in Phase 1/2 clinical trials for advanced solid tumors including lung cancer, demonstrating favorable tolerability with clinical activity including partial responses.
- ACR-6840 ACR-6840 is a development candidate targeting CDK11, being developed using the AP3 platform, with plans for Investigational New Drug (IND) application submission in Q4 2026.
- OncoSignature Companion Diagnostic OncoSignature is a drug-tailored, automated, quantitative proteomic tissue imaging assay designed to identify patients most likely to benefit from Acrivon's drug candidates by measuring disease-driving protein activity from pretreatment tumor biopsies. It has received FDA Breakthrough Device Designation for endometrial and ovarian cancer patient selection.
Quantifiable outcome
- 52% confirmed overall response rate in serous endometrial cancer patients (ACR-368 Phase 2b)
- +3 more outcomes
Companies that use Acrivon Therapeutics
Customer profileSegments3 records
Ideal customer profiles2 records
Acrivon Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
Acrivon Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Eli Lilly and CompanycoreACR-368 (also known as Prexasertib, LY2606368) was in-licensed from Lilly. Acrivon acquired rights to develop and commercialize this clinically-advanced CHK1/2 inhibitor for oncology indications using its proprietary AP3 platform and OncoSignature companion diagnostic for patient selection.
Scale indicators11 records
Recent moves6 records
Expansion highlights5 records
Acrivon Therapeutics competitors and assessment
Company assessmentDirect peers
- Repare Therapeutics: Clinical-stage precision oncology company using a proprietary genomics- and CRISPR-based SNIPRx platform to develop synthetic-lethal targeted therapies with patient-selection biomarkers, comparable to Acrivon's AP3 platform-driven, biomarker-stratified approach.
- Tango Therapeutics: Precision oncology company leveraging functional genomics and synthetic lethality to develop targeted cancer therapies with biomarker-driven patient selection, overlapping directly with Acrivon's proteomics-driven precision oncology strategy.
- Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric kinase inhibitors against oncogenic mutations, using its proprietary Mutation-Allostery-Pharmacology platform, comparable to Acrivon's platform-based, biomarker-driven targeted oncology approach.
- Relay Therapeutics: Precision oncology company combining computational methods with structural biology and biochemistry to develop targeted therapies such as PI3Kα inhibitors, with a similar platform-driven approach to Acrivon's AP3.
- Foghorn Therapeutics: Clinical-stage oncology company targeting chromatin regulatory systems through its proprietary Gene Traffic Control platform, comparable to Acrivon as a platform-based precision oncology company developing multiple targeted candidates.
- Schrödinger: Computational drug discovery platform company applying physics-based modeling and predictive analytics to design precision oncology therapeutics, comparable to Acrivon's AI/ML-enabled KaiSR and AP3 platform approach.
- Zentalis Pharmaceuticals: Clinical-stage precision oncology company developing small molecules targeting fundamental cancer pathways, with a pipeline that overlaps Acrivon's focus on gynecologic and other solid tumor indications.
Emerging players
- Recursion Pharmaceuticals: Tech-enabled drug discovery company combining high-throughput biology with AI/ML to identify precision oncology candidates, comparable as an AI-driven precision oncology platform competitor to AP3.
- Exscientia: AI-driven precision medicine company combining generative AI with patient-derived data to design targeted oncology drugs, comparable to Acrivon's computational platform and biomarker-driven strategy.
- Lantern Pharma: Clinical-stage precision oncology company using AI and genomic biomarker platforms (RADR) to develop and repurpose oncology drugs, comparable in its AI-platform plus companion-diagnostic model to Acrivon.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Acrivon Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Acrivon Therapeutics leadership team
Management profileNumber of profiles
Profiles8 records
Acrivon Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Acrivon Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Acrivon Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Acrivon Therapeutics
What does Acrivon Therapeutics do?
Acrivon Therapeutics is a clinical-stage precision oncology company developing targeted cancer therapies paired with proprietary OncoSignature companion diagnostics. Its lead program ACR-368 (a CHK1/2 inhibitor in-licensed from Eli Lilly) is in registrational-intent Phase 2b for endometrial cancer and platinum-resistant ovarian cancer, supported by the AP3 platform that uses mass spectrometry-based phosphoproteomics with automated tumor biopsy imaging to match drug mechanisms to protein-activity-driven tumor biology rather than genomic alterations.
Is Acrivon Therapeutics a public or private company?
Acrivon Therapeutics is a public company. It is classified as public and is currently operating.
When was Acrivon Therapeutics founded?
Acrivon Therapeutics was founded in 2018. It employs 51 to 100 people.
Where is Acrivon Therapeutics based?
Acrivon Therapeutics is headquartered in Cambridge, United States, in the North America region.
How does Acrivon Therapeutics make money?
One revenue line is on record: drug Development and Commercialization.
Who are Acrivon Therapeutics's main competitors?
Direct peers on record are Repare Therapeutics, Tango Therapeutics, Black Diamond Therapeutics, Relay Therapeutics, Foghorn Therapeutics, Schrödinger and Zentalis Pharmaceuticals. Emerging players are Recursion Pharmaceuticals, Exscientia and Lantern Pharma.
Does Acrivon Therapeutics have an API?
No public API is recorded for Acrivon Therapeutics.
What industry is Acrivon Therapeutics in?
Acrivon Therapeutics's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.